COVID-19 Antibody Treatments Continue Well After FDA Deauthorization

Despite the best efforts of the US Food and Drug Administration (FDA), the use of Eli Lilly and Regeneron’s monoclonal COVID-19 antibody treatments is still prevalent. Nearly 160,000 doses of the therapeutics have been given since the two were deauthorized by the FDA this January. An estimate of the total healthcare cost is approximately $71 million.

According to Fraiser Kansteiner, “Use of Eli Lilly’s bamlanivimab-etesevimab and Regeneron’s casirivimab-imdevimab peaked during the week of Dec. 22, 2021, when 91,036 total doses were reported, according to a new JAMA Network study. While mAb use “gradually declined” after FDA deauthorization and dropped throughout the remainder of the study period—which ran until June 29—Lilly’s and Regeneron’s antibody combos continued to be administered after FDA deauthorization on Jan. 24, the study authors note.”

To read more, click here.

(Source: Fierce Pharma, September 2^nd, 2022)